When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Recommendations exist for Dengvaxia® (CYD-TDV) vaccination in individuals aged 9-45/60 with prior dengue virus (DENV) infection in endemic areas.
• A key question is the appropriate timing for vaccination post-DENV infection, relevant for all live vaccines in these regions.

Purpose of the Study:

• To review immunological and practical considerations for live vaccination following DENV infection.
• To provide evidence for health authorities and practitioners on vaccine policy and program implementation.

Main Methods:

• Review and discussion of immunological responses to DENV infection.
• Analysis of practical challenges in determining vaccination timing after infection.
• Evaluation of existing guidance for live vaccine use in endemic settings.

Main Results:

• The timing of vaccination post-DENV infection can influence the success and benefit of live vaccines due to the nature and kinetics of immune responses.
• Practical challenges exist in pinpointing the exact date of DENV infection, necessitating vaccination during defined periods.
• Evidence-based guidance is needed for consistent vaccine policy and program implementation.

Conclusions:

• Vaccination timing post-DENV infection requires careful consideration of immune dynamics and practical logistics.
• Further evidence is needed to inform optimal vaccination schedules for live vaccines like Dengvaxia® in endemic populations.
• Clearer guidelines are essential for effective vaccine policy and program delivery.